BioPharmSignal logoBioPharmSignal

Biotech News

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Instil Bio (TIL)Instil BioCompany update

DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr.

Related news

TILInstil Bio2026-08-13 21:00 EST

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

GERNGeron2026-07-13 12:00 EST

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

ERASErasca2026-08-10 12:00 EST

Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

View all latest news

Instil Bio

Therapeutics Acquisition Strategy Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutics. It is evaluating acquisitions, in-licensing transactions, and related opportunities that could provide access to new drug candidates. Portfolio Rebuilding Following the wind-down of prior internal...

Recent company news

TILInstil Bio2026-08-13 21:00 EST

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-05-15 11:00 EST

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-03-27 11:00 EST

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TILInstil Bio2026-01-06 12:00 EST

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

TILInstil Bio2025-11-13 12:00 EST

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
7.58 USD
Market cap
55M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States